Discontinued — last reported Q4 '18
Biogen Contingent consideration fair value adjustment increased by 266.1% to $20.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 113.5%, from $9.60M to $20.50M.
A gain (reduction in liability) often suggests that milestones are less likely to be met, while a loss (increase in liability) suggests higher confidence in achieving those milestones.
This metric reflects the periodic revaluation of liabilities related to contingent consideration, such as milestone paym...
Specific to companies that utilize earn-out structures in their M&A activity.
nee_contingent_consideration_fair_value_adjustment| Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $23.80M | $9.60M | $13.20M | $5.60M | $20.50M |
| QoQ Change | — | — | — | — | -59.7% | +37.5% | -57.6% | +266.1% |
| YoY Change | — | — | — | — | — | — | -76.5% | +113.5% |